ArticleTranslational lung cancer research2025
Prognostic factors affecting mortality in elderly, low body mass index, and poor performance status groups with lung cancer: analysis of the 2016 Korean Association of Lung Cancer Registry (KALC-R) database.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remarkable response to personalized combination immunotherapy of nivolumab plus ipilimumab in an 84-year-old patient with locally advanced squamous cell carcinoma: a case report.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent advancements in lung cancer treatment have brought about a paradigm shift that raises the possibility of treatment for populations who were previously not considered for lung cancer therapy. In light of these developments, it is necessary to reassess the treatment outcomes and feasibility of such advanced therapies in vulnerable populations. This study aims to provide real-world evidence on treatment outcomes across varying clinical conditions, with a focus on patients with frail conditions such as old age, low BMI, or reduced performance status, who are often underrepresented. Methods: This study analyzed data from the Korean Association of Lung Cancer Registry (KALC-R) cohort-the third nationwide survey, a multi-center cancer registry from 13 regional cancer centers and 38 hospitals from which significant number of registrations were made. In 2016, the KALC-R registered 2,808 patients who were newly diagnosed with lung cancer. Results: Older age, male sex, lower body mass index (BMI), squamous cell carcinoma, poor performance status, lower lung function, higher clinical stage and non-surgical treatment or best supportive care only were significant factors for mortality in non-small cell lung cancer (NSCLC) patients. Also, in patients with small cell lung cancer (SCLC), older age, lower BMI, poor performance status, higher clinical stage, and best supportive care only compared to anti-cancer treatment were significantly associated with mortality. Both NSCLC and SCLC patients who receive best supportive care only have a higher risk of mortality compared to those who receive surgical treatment among elderly patients (≥65 years), patients with poor performance status, and those with low BMI (<20 kg/m Conclusions: A select group of patients with vulnerable conditions, such as old age, low BMI, and poor performance status, may benefit from active anti-cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.